Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 1 reviews · Neonatal

No studies found 6 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5a.Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation

The review found no eligible studies for this question.

1 finding from 1 review